Avanos Medical, Inc. (AVNS)

Avanos Medical's stock price has experienced a significant decline of 47.55% over the last year and a -5.53% change over the last six months as of October 26, 2025. In Q2 2025, Avanos Medical reported a diluted loss per share at $1.66 and adjusted diluted earnings per share at $0.17, with net sales increasing by 1.9% to $175.0 million. The company recorded a non-cash impairment charge of $77.0 million in its Pain Management & Recovery segment during Q2 2025. Avanos divested its Hyaluronic Acid product line on July 31, 2025, and acquired Nexus Medical, LLC, in September 2025. Scott Galovan was appointed as Senior Vice President, Chief Financial Officer, and David Pacitti joined the Board of Directors on August 5, 2025. Delays in implementing reimbursement decisions under the NOPAIN Act impacted the surgical pain business, but Avanos' ON-Q and ambIT infusion pumps are expected to receive separate payment under the NOPAIN Act effective January 1, 2025. Avanos Medical insiders have bought more company stock than they have sold in the past three months, with Chairman of the Board Gary Blackford purchasing 60,000 shares in August 2025. Avanos Medical, Inc. is scheduled to webcast a conference call discussing its third-quarter 2025 financial results on November 5, 2025.

Specific information regarding the demand seasonality for Avanos Medical, Inc.'s products and services was not explicitly detailed in the provided search results. While some financial reports mention a "challenging market environment for some of our product categories" in their 2025 guidance, this does not necessarily indicate seasonal demand patterns.

Avanos Medical, Inc. is a medical technology company that develops and markets medical devices to improve patient outcomes, operating in the Medical sector, specifically in the Medical Equipment, Medical Specialties, or MED INSTRUMENTS industry. The company focuses on pain management with products like the ON-Q Pain Relief System, Game Ready, COOLIEF Cooled Radiofrequency System, and ambIT surgical pain pumps. In enteral feeding, they offer MIC-KEY enteral feeding tubes, CORTRAK 2 Enteral Access System, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. For respiratory care, they provide patient interfaces, breathing circuits, and related disposables for noninvasive ventilation, oxygen therapy, airway management, and IV therapy products.

Avanos Medical, Inc. is headquartered in Alpharetta, Georgia, U.S., and has a global presence, selling its products in over 90 countries. The company supports hospitals, surgical centers, and home healthcare providers through direct sales teams and distributor partnerships. Avanos operates 8 principal medical device production facilities and has a presence in key markets across North America, Europe, Asia Pacific, and Latin America, including countries like China, Thailand, India, Canada, Germany, Japan, Australia, and the US.

No specific events significantly impacting Avanos Medical, Inc.'s brand reputation (either positively or negatively) within the past year (October 2024 - October 2025) were explicitly identified. The company's news releases primarily focus on financial results, acquisitions, and leadership changes.

Avanos Medical, Inc. has a high level of institutional ownership, with 95.17% to 97.22% of the stock held by institutions, and insiders hold between 2.64% and 3.51% of the stock. Major institutional owners include Blackrock Inc., Vanguard Group Inc., T Rowe Price Investment Management Inc., State Street Global Advisors, Inc., Pacer Advisors Inc., Voya Investment Management LLC, SG Americas Securities LLC, and VIRGINIA RETIREMENT SYSTEMS ET Al. The largest individual shareholder is Joseph Fralin Woody, owning 402,776 shares, representing 0.87% of the company.